LabCorp Announces Availability of Newly Approved Viral Load Assay for Hepatitis C Virus

  LabCorp Announces Availability of Newly Approved Viral Load Assay for
  Hepatitis C Virus

  LabCorp becomes the First Major Clinical Reference Laboratory to Offer the
              Roche COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0

Business Wire

BURLINGTON, N.C. -- June 17, 2013

Laboratory Corporation of America^® Holdings (LabCorp^®) (NYSE: LH) today
announced that it is offering the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0.
With enhanced sensitivity, this quantitative viral load assay for Hepatitis C
virus (HCV) enables more accurate assessments of response to antiviral
therapy.

As the first major clinical reference laboratory to offer the COBAS
AmpliPrep/COBAS TaqMan HCV Test, v2.0, LabCorp can now provide physicians with
a quantitative HCV viral load assay that has a lower limit of detection and
quantification (15 IU/mL) than existing qualitative HCV assays (10-50 IU/mL).
Viral load determinations influence decisions related to many aspects of
antiviral HCV therapy, including treatment selection and adjustments.
Following treatment initiation, periodic measurements of HCV viral load allows
the clinician to assess the success of treatment.

An estimated 3.2 million people in the U.S. (and 170 million worldwide) are
chronically infected with HCV, which if left undiagnosed and untreated can
lead to liver fibrosis, cirrhosis and hepatocellular carcinoma. The Centers
for Disease Control and Prevention (CDC) estimates that nearly half of the
U.S. HCV population is currently undiagnosed, and the slow and often silent
onset of HCV disease presentation has prompted more aggressive efforts to
proactively diagnose and treat HCV infection. Recently, the CDC expanded its
HCV screening recommendations from “high risk behavior groups” to include all
individuals born between 1945-1965, a birth cohort that CDC estimates to
include a majority of HCV infected individuals in the U.S. As part of this
initiative, newly diagnosed individuals are encouraged to seek medical care
and treatment for their HCV infection. The expanded availability through
LabCorp of the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 is particularly
timely, as the CDC recommendation is expected to result in the identification
of additional HCV-infected patients and an increased demand for antiviral
treatment regimens.

“LabCorp is proud of its longstanding and prominent role of providing
innovative and novel diagnostic tests to assist physicians in treating and
managing chronic HCV infection,” said Dr. Mark Brecher, LabCorp’s Chief
Medical Officer. “The COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 is another
valuable addition to the Company’s comprehensive portfolio of assays that
characterize the Hepatitis C virus, disease course and the patient’s optimal
treatment path.”

About LabCorp^®

Laboratory Corporation of America^® Holdings, an S&P 500 company, is a pioneer
in commercializing new diagnostic technologies and the first in its industry
to embrace genomic testing. With annual revenues of $5.7 billion in 2012, over
34,000 employees worldwide, and more than 220,000 clients, LabCorp offers more
than 4,000 tests ranging from routine blood analyses to reproductive genetics
to companion diagnostics. LabCorp furthers its scientific expertise and
innovative clinical testing technology through its Specialty Testing Group:
The Center for Molecular Biology and Pathology, National Genetics Institute,
ViroMed Laboratories, Inc, The Center for Esoteric Testing, Litholink
Corporation, Integrated Genetics, Integrated Oncology, DIANON Systems, Inc,
Monogram Biosciences, Inc, Colorado Coagulation, Cellmark Forensics, MedTox,
and Endocrine Sciences. LabCorp conducts clinical trials testing through its
LabCorp Clinical Trials division. LabCorp clients include physicians,
government agencies, managed care organizations, hospitals, clinical labs, and
pharmaceutical companies. To learn more about our company, visit our Web site
at: www.labcorp.com.

This press release contains forward-looking statements. Each of the
forward-looking statements is subject to change based on various important
factors, including without limitation, competitive actions in the marketplace
and adverse actions of governmental and other third-party payors. Actual
results could differ materially from those suggested by these forward-looking
statements. Further information on potential factors that could affect
LabCorp’s financial results is included in the Company’s Form 10-K for the
year ended December 31, 2012, and subsequent SEC filings.

Contact:

LabCorp^®
Investor/Media Contact:
Stephen Anderson, 336-436-5076
Company Information: www.labcorp.com
 
Press spacebar to pause and continue. Press esc to stop.